Phase 2 Cardiomyopathy Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged between 18 and 75 years old who have been diagnosed with dilated cardiomyopathy (a condition where the heart muscle is weakened and enlarged).
• People who are able to confirm they understand the risks, benefits, and treatment options involved, and who (or whose legal representative) are willing to sign a consent form before taking part.
• People diagnosed with heart failure where the heart's pumping function is significantly reduced, who have been on the maximum tolerated standard heart failure medications for at least 3 months, whose heart pumps less than 35% of its capacity, and whose symptoms fall within a specific range of severity (NYHA class IIIB–IV and INTERMACS class 3–6) (confirm with trial site).
• People whose blood test results show: red blood cell levels (hematocrit) above 30%, a type of white blood cell (lymphocytes) above a certain level, and platelets above a certain level (confirm exact values with trial site).

Who may not be able to join:

• People who have had a heart attack, unstable chest pain, stroke, or a mini-stroke (transient ischemic attack) within the 12 weeks before enrolling.
• People who have had a cardiac resynchronisation therapy (CRT) device implanted within the 12 weeks before enrolling, or who are planning to have one implanted.
• People who have previously had a heart transplant or a mechanical heart pump device implanted, or who are planning to have one.
• People whose heart failure is caused by conditions other than dilated cardiomyopathy, such as blocked arteries, stiff heart muscle, active heart inflammation, scarring around the heart, thickened heart muscle, long-term high blood pressure, birth-related heart defects, or uncorrected valve disease.
• People who have a dangerously slow heart rate with symptoms, or a significant electrical conduction problem in the heart (second or third degree heart block).
• People who have an active autoimmune disease that currently requires medication to suppress the immune system.
• People who have a blood clot in the lungs (pulmonary embolism).
• People with a history of tuberculosis.
• People with a history of severe kidney failure or who require dialysis, or whose creatinine (a measure of kidney function) is above a certain level.
• People with uncontrolled low platelet counts or blood clotting problems, or who have active bleeding that cannot be corrected.
• People with significantly elevated liver enzyme levels or raised bilirubin (a marker of liver function) in their blood.
• People with a history of serious ongoing infection, blockage in the liver or bile ducts, or cancer.
• People with active hepatitis B (at a certain level of virus detected in the blood), hepatitis C, syphilis, or HIV; or any uncontrolled serious infection caused by fungus, bacteria, a virus, or another pathogen.
• People in a state of severe haemodynamic instability, such as shock (where the body's organs are not receiving enough blood).
• People who are pregnant or who may become pregnant during the trial.
• People who have known contraindications (reasons they should not receive) to any of the study drugs or tests involved.

Important: Always verify eligibility with the trial site directly before applying.